Myocardial Infarction Guided Emergency Hematopoiesis: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Aldo Moggio.

“Emergency hematopoiesis” occurs after myocardial infarction (MI) and includes different processes: (1) the amplification of leukocyte production, (2) the maturation of alternative leukocyte subsets and (3) the release of myeloid cells from primary and secondary hematopoietic organs.

  • myocardial infarction
  • hematopoiesis
  • myeloid cells
  • extracellular signaling

1. Myocardial Infarction Guided Emergency Hematopoiesis

While hematopoiesis continuously supplies new blood cells in homeostatic conditions, hematopoiesis may react to external stressors/triggers. The response of the hematopoietic system is driven by several signals, either local or external. In case of myocardial infarction (MI), cardiac cells (such as mast cells, macrophages, and CMcardiomyocytes (CM)) trigger a massive recruitment of circulating leukocytes through the release of soluble factors. In parallel, the BMbone marrow (BM) responds to the remote injury by releasing hematopoietic progenitors, expanding the immune cell pool and promoting the maturation of distinct leukocyte subsets [44][1]. To meet the high demand of leukocytes, hematopoiesis may also take place outside the BM, in the spleen (extramedullary hematopoiesis) [27,87,88,89,90][2][3][4][5][6]. “Emergency hematopoiesis” occurs after MI and includes different processes: (1) the amplification of leukocyte production, (2) the maturation of alternative leukocyte subsets and (3) the release of myeloid cells from primary and secondary hematopoietic organs.

2. Progenitor Amplification

The BM responds to MI and transiently increases production of leukocytes. This process passes through the amplification of hematopoietic progenitor cells in the BM. Indeed, positron emission tomography (PET) analysis of the pelvic bone in patients with MI showed increased metabolic activities in the BM, probably reflecting increased proliferation of hematopoietic stem cells (HSCs). In line, the analysis of murine models showed that MI drives the activation of Wnt pathway, which regulates the proliferation of hematopoietic stem and progenitor cells (HSPCs) [91][7]. In a study by Dutta and colleagues, it was shown that MI supports the proliferation of CCR2+ HSCs. Through the expression of Mtg16, CCR2+ progenitors are biased toward a myeloid phenotype, thus present a source of neutrophils, monocytes and macrophages, the cellular protagonists of the inflammatory phase following MI [84][8]. Using parabiosis, mice with a joined circulation, and left anterior descending (LAD) coronary artery ligation, the same research group demonstrated that MI increased levels of blood-borne, circulating factors that stimulate proliferation of HSCs. In particular IL-1β, binding the receptor (IL-1R1) expressed by HSCs and non-hematopoietic cells of the niches, induced activation of the BM and production of neutrophils and monocytes [85][9].
Together with IL1β, several other factors act directly on hematopoiesis during the inflammatory phase of the MI including granulocyte colony-stimulating factor (G-CSF), granulocyte–macrophage colony-stimulating factor (GM-CSF), CXCL12 and CCL2. These factors can modulate proliferation and differentiation of hematopoietic progenitors during the course of MI [62,92][10][11].
G-CSF induces maturation, survival, proliferation, and functional activation of granulocytes. Moreover, it also plays a crucial role in the mobilization of granulocytes and HSPCs from the BM into the peripheral circulation [62,93][10][12]. Indeed, G-CSF inhibits macrophage-mediated retention signals in the BM and enhances sympathetic nervous system (SNS)-mediated progenitor release [82][13]. As mentioned before, the SNS has a fundamental role in homeostatic hematopoiesis. Additionally, the SNS is also involved in the regulation of the BM in case of MI. Noradrenaline increased in the BM of mice after MI. As consequence, Nes+ mesenchymal stem and stromal cells (MSC), expressing β3AR, decrease the expression of Cxcl12 and Scf. The downregulation of those retention factors stimulates the release of HSCs into the blood [94][14]. Due to the capability to regulate different processes, the role of G-CSF in case of MI has been extensively studied, especially as possible pro-regenerative treatment. However, results from studies that evaluated the therapeutic potential of G-CSF are conflicting. Several studies showed that G-CSF treatment, administered before and after MI onset, may be beneficial inducing a better regeneration of cardiac tissue. On the other hand, more recent studies showed that G-CSF fuels inflammation in the cardiac tissue [95,96,97][15][16][17].
GM-CSF is produced by different cell types including leukocytes, fibroblasts and endothelial cells (ECs). Like in the case of G-CSF, GM-CSF induces BM cell mobilization and was thus studied as pro-regenerative factor after MI. Alone or in combination with other cytokines, G-CSF can stimulate survival, proliferation and differentiation of different myeloid cells like neutrophils, eosinophils, monocytes and DCsnd dendritic cells (DCs). In particular GM-CSF, in combination with tumor necrosis factor-α (TNFα) and IL4, induces the differentiation of myeloid cells into DCs [93][12]. Although GM-CSF may confer cardiac reparative benefits when administered together with other growth factors, current evidence suggests that GM-CSF-induced cellular infiltration and molecular changes cause more damage than benefits in the post-infarction period. A study conducted by Anzai and colleagues showed that cardiac fibroblasts are the major source of GM-CSF in the first days after MI, in both mice and humans. GM-CSF is produced in the infarcted heart and promotes myelopoiesis in the BM by targeting a specific progenitor subset that gives rise to neutrophils and Ly6CHI monocytes. Moreover, the same study showed the GM-CSF impairs wound healing through increased leukocyte accumulation after MI (primarily neutrophils and monocytes). Indeed, GM-CSF induces expression of immune cell-attracting chemokines such as Cxcl2, Ccl2, Ccl3, Ccl5, and Ccl7 [98][18].
HSCs express MCSF1R, the receptor for macrophage colony-stimulating factor (M-CSF), and react to M-CSF stimulation with differentiation toward monocytes in vitro. Indeed, M-CSF is a cytokine that regulates the differentiation, proliferation, and survival of monocytic progenitor cells [99,100][19][20]. In steady state mice, perivascular stromal cells and osteoblastic cells of the hematopoietic niches are the major sources of M-CSF [101][21]. The comparison of two transgenic mouse lines, Csf1r−/Csf1r− and Csf1op/Csf1op, confirmed the fundamental role of M-CSF in the production and differentiation of monocytes. Both mouse lines showed a reduced number of circulating monocytes and a decreased number of tissue resident macrophages [102][22]. In case of MI, different animal models showed an increased expression of M-CSF in cardiac tissue [103][23]. Another study showed that the administration of recombinant M-CSF in mice with MI induces the egress of monocytes from the BM via modulating the CXC-chemokine receptor 4 (CXCR4-CXCL12)-XC-chemokine ligand 12 (CXCL12) axis [104][24]. 

3. Development of Alternative Phenotypes of Myeloid Cells (Qualitative Alterations)

Several studies showed that pathological conditions such as infections, tumors or tissue injuries stimulate the production of myeloid cell with alternative phenotypes [25,106,107][25][26][27]. For instance, in a mouse model of cancer, distinct subpopulations of neutrophils have been identified. These different subpopulations can be distinguished according to their densities: “normal” and “low-density” neutrophils (LDNs). LDNs showed features associated with pro-tumor activity [108][28]. Another study identified a subtype of neutrophil with DC-like phenotype which express MHCII and CD11c. DC-like neutrophils differentiate from canonical neutrophils (with a rate <2%) in humans and mice under local and systemic inflammation [109][29]. Similar to neutrophils, monocytes with alternative phenotypes were identified. For instance, monocytes may develop a “neutrophil-like” phenotype (NeuMo) in response to LPS injection or monocytes may express Ceacam1 and Msr1 (SatM) in case of pulmonary fibrosis [110,111][30][31]. Further, a subtype of Ly6CHI monocytes, expressing Sca-1 and MHCII, was found to be induced by interferon gamma (INFγ) [112][32]. Finally, Ym1+Ly6CHI monocytes are released from the BM during the resolution phase of colitis [113][33].
There are no evidences regarding particular subsets of circulating monocytes or neutrophils triggered by MI, but future studies may fill this gap [90,107][6][27]. The general view is that myeloid cells acquire effector functions as a result of interactions with local signals/the local environment in the ischemic area of the heart. However, a recent study showed that the type I interferon (IFN) response to ischemic cardiac injury begins “remotely” already in the BM. Specifically, the authors showed that myeloid cells are characterized by the expression of IFN-stimulated genes after the MI, already at the level of the BM. This response occurs not only in monocytes or monocyte-derived macrophages, but also in neutrophils [114][34]. Another work identified the expansion of particular subsets of monocytes (CD14+ HLA-DR−) and immature neutrophils (CD16+ CD66b+CD10−) in the blood of patients with MI [115][35]. These two studies provide a clear confirmation that MI induces quantitative and qualitative changes in the myeloid repertoire.

4. Extramedullary Emergency Source of Myeloid Cells

Although the BM is the primary tissue responsible for the production of leukocytes, extramedullary hematopoiesis takes place in the spleen after the onset of the MI. As shown by Swirski and colleagues, the spleen is a reservoir of Ly6CHI and Ly6CLOW monocytes and, in case of splenectomy, leukocyte supply to the infarcted heart is reduced [116][36]. Within the first days after MI, a huge quantity of monocytes is released from the splenic subcapsular red pulp into the circulation. The mobilization of monocytes is driven by the interaction of angiotensin II with its receptors expressed by monocytes [117][37]. Consistently, the recent development of a high-density lipoprotein-derived nanotracer, which allows non-invasive in vivo tracking of myeloid cells, demonstrates that in case of permanent or transient LAD ligation, a significant quantity of myeloid cells is mobilized from the spleen [118][38]. As a consequence, the number of splenic Ly6CHI monocytes decrease starting from day 1 post-MI and is restored within 4 days [119][39]. Splenic monocytes derive from maturation of HSPCs which egressed the BM and seeded the spleen prior. HSPCs are retained in the spleen by the presence of macrophages expressing vascular cell adhesion protein-1 (VCAM-1) [120][40]. Further, Grisanti and colleagues using chimeric mice with β2AR knockout reconstituted BM showed that the deletion of the β2-adrenoreceptor (β2AR) induces retention of leukocytes in the spleen due to an overexpression of VCAM-1. Moreover, the expression of both VCAM-1 and CCR2 appears to be regulated by β2AR signaling [121,122][41][42]. Further, these and others studies demonstrated the efficacy of β-blockers as treatment for MI [122,123,124][42][43][44]. Finally, the administration of bromodeoxyuridine (BrdU) showed a robust expansion of myeloid progenitor cells (MDPs) in the spleen after LAD ligation. Similar to the BM, IL-1β regulates the production of splenic monocytes after MI [125][45].
Splenic neutrophils take part in the response to bacteria, like in the case of Streptococcus pneumoniae infection, and it has been demonstrated that pancreatic carcinoma or sepsis causes extramedullary granulopoiesis [126,127][46][47]. Unlike monocytes, it is not entirely clear whether the spleen also functions a source of neutrophils in case of MI, so further studies are needed to clarify this aspect.

References

  1. Libby, P.; Nahrendorf, M.; Swirski, F.K. Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease. J. Am. Coll. Cardiol. 2016, 67, 1091–1103.
  2. Guilliams, M. Developmental and Functional Heterogeneity of Monocytes. Immunity 2018, 49, 595–613.
  3. Bronte, V.; Pittet, M.J. The Spleen in Local and Systemic Regulation of Immunity. Immunity 2013, 39, 806–818.
  4. Abdali, A.; Marinković, G. Assessment of Medullary and Extramedullary Myelopoiesis in Cardiovascular Diseases. Pharmacol. Res. 2021, 169, 105663.
  5. Grieshaber-Bouyer, R.; Nigrovic, P.A. Neutrophil Heterogeneity as Therapeutic Opportunity in Immune-Mediated Disease. Front. Immunol. 2019, 10, 346.
  6. Wolf, A.A.; Yáñez, A.; Barman, P.K.; Goodridge, H.S. The Ontogeny of Monocyte Subsets. Front. Immunol. 2019, 10, 1642.
  7. Assmus, B.; Iwasaki, M.; Schachinger, V.; Roexe, T.; Koyanagi, M.; Iekushi, K.; Xu, Q.; Tonn, T.; Seifried, E.; Liebner, S.; et al. Acute Myocardial Infarction Activates Progenitor Cells and Increases Wnt Signalling in the Bone Marrow. Eur. Heart J. 2012, 33, 1911–1919.
  8. Dutta, P.; Sager, H.B.; Stengel, K.R.; Naxerova, K.; Courties, G.; Saez, B.; Silberstein, L.; Heidt, T.; Sebas, M.; Sun, Y.; et al. Myocardial Infarction Activates CCR2+ Hematopoietic Stem and Progenitor Cells. Cell Stem Cell 2015, 16, 477–487.e5.
  9. Sager, H.B.; Heidt, T.; Hulsmans, M.; Dutta, P.; Courties, G.; Sebas, M.; Wojtkiewicz, G.R.; Tricot, B.; Iwamoto, Y.; Sun, Y.; et al. Targeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial Infarction. Circulation 2015, 132, 1880–1890.
  10. Crane, G.M.; Jeffery, E.; Morrison, S.J. Adult Haematopoietic Stem Cell Niches. Nat. Rev. Immunol. 2017, 17, 573–590.
  11. Tobin, S.W.; Alibhai, F.J.; Weisel, R.D.; Li, R.-K. Considering Cause and Effect of Immune Cell Aging on Cardiac Repair after Myocardial Infarction. Cells 2020, 9, 1894.
  12. Sanganalmath, S.K.; Abdel-Latif, A.; Bolli, R.; Xuan, Y.-T.; Dawn, B. Hematopoietic Cytokines for Cardiac Repair: Mobilization of Bone Marrow Cells and Beyond. Basic Res. Cardiol. 2011, 106, 709–733.
  13. Chow, A.; Lucas, D.; Hidalgo, A.; Méndez-Ferrer, S.; Hashimoto, D.; Scheiermann, C.; Battista, M.; Leboeuf, M.; Prophete, C.; van Rooijen, N.; et al. Bone Marrow CD169+ Macrophages Promote the Retention of Hematopoietic Stem and Progenitor Cells in the Mesenchymal Stem Cell Niche. J. Exp. Med. 2011, 208, 261–271.
  14. Dutta, P.; Courties, G.; Wei, Y.; Leuschner, F.; Gorbatov, R.; Robbins, C.S.; Iwamoto, Y.; Thompson, B.; Carlson, A.L.; Heidt, T.; et al. Myocardial Infarction Accelerates Atherosclerosis. Nature 2012, 487, 325–329.
  15. Delgaudine, M.; Gothot, A.; Beguin, Y. Spontaneous and Granulocyte–Colony-Stimulating Factor-Enhanced Marrow Response and Progenitor Cell Mobilization in Mice after Myocardial Infarction. Cytotherapy 2010, 12, 909–918.
  16. D’Amario, D.; Leone, A.M.; Borovac, J.A.; Cannata, F.; Siracusano, A.; Niccoli, G.; Crea, F. Granulocyte Colony-Stimulating Factor for the Treatment of Cardiovascular Diseases: An Update with a Critical Appraisal. Pharmacol. Res. 2018, 127, 67–76.
  17. Dawn, B.; Guo, Y.; Rezazadeh, A.; Huang, Y.; Stein, A.B.; Hunt, G.; Tiwari, S.; Varma, J.; Gu, Y.; Prabhu, S.D.; et al. Postinfarct Cytokine Therapy Regenerates Cardiac Tissue and Improves Left Ventricular Function. Circ. Res. 2006, 98, 1098–1105.
  18. Anzai, A.; Choi, J.L.; He, S.; Fenn, A.M.; Nairz, M.; Rattik, S.; McAlpine, C.S.; Mindur, J.E.; Chan, C.T.; Iwamoto, Y.; et al. The Infarcted Myocardium Solicits GM-CSF for the Detrimental Oversupply of Inflammatory Leukocytes. J. Exp. Med. 2017, 214, 3293–3310.
  19. Mossadegh-Keller, N.; Sarrazin, S.; Kandalla, P.K.; Espinosa, L.; Stanley, E.R.; Nutt, S.L.; Moore, J.; Sieweke, M.H. M-CSF Instructs Myeloid Lineage Fate in Single Haematopoietic Stem Cells. Nature 2013, 497, 239–243.
  20. Metcalf, D. Hematopoietic Cytokines. Blood 2008, 111, 485–491.
  21. Zhang, J.; Wu, Q.; Johnson, C.; Olsson, A.; Slaughter, A.; May, M.L.; Weinhaus, B.; Bowers, E.; Engel, J.D.; Jiang, J.X.; et al. Spatial Mapping of Myelopoiesis Reveals the Bone Marrow Niche for Monocyte Dendritic Cell Progenitors. Blood 2019, 134, 528.
  22. Dai, X.-M.; Ryan, G.R.; Hapel, A.J.; Dominguez, M.G.; Russell, R.G.; Kapp, S.; Sylvestre, V.; Stanley, E.R. Targeted Disruption of the Mouse Colony-Stimulating Factor 1 Receptor Gene Results in Osteopetrosis, Mononuclear Phagocyte Deficiency, Increased Primitive Progenitor Cell Frequencies, and Reproductive Defects. Blood 2002, 99, 111–120.
  23. Dewald, O.; Ren, G.; Duerr, G.D.; Zoerlein, M.; Klemm, C.; Gersch, C.; Tincey, S.; Michael, L.H.; Entman, M.L.; Frangogiannis, N.G. Of Mice and Dogs. Am. J. Pathol. 2004, 164, 665–677.
  24. Morimoto, H.; Takahashi, M.; Shiba, Y.; Izawa, A.; Ise, H.; Hongo, M.; Hatake, K.; Motoyoshi, K.; Ikeda, U. Bone Marrow-Derived CXCR4+ Cells Mobilized by Macrophage Colony-Stimulating Factor Participate in the Reduction of Infarct Area and Improvement of Cardiac Remodeling after Myocardial Infarction in Mice. Am. J. Pathol. 2007, 171, 755–766.
  25. Manz, M.G.; Boettcher, S. Emergency Granulopoiesis. Nat. Rev. Immunol. 2014, 14, 302–314.
  26. Iqbal, A.J.; Fisher, E.A.; Greaves, D.R. Inflammation—A Critical Appreciation of the Role of Myeloid Cells. Myeloid Cells Health Dis. A Synth. 2017, 17, 325–342.
  27. Trzebanski, S.; Jung, S. Plasticity of Monocyte Development and Monocyte Fates. Immunol. Lett. 2020, 227, 66–78.
  28. Sagiv, J.Y.; Michaeli, J.; Assi, S.; Mishalian, I.; Kisos, H.; Levy, L.; Damti, P.; Lumbroso, D.; Polyansky, L.; Sionov, R.V.; et al. Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer. Cell Rep. 2015, 10, 562–573.
  29. Fites, J.S.; Gui, M.; Kernien, J.F.; Negoro, P.; Dagher, Z.; Sykes, D.B.; Nett, J.E.; Mansour, M.K.; Klein, B.S. An Unappreciated Role for Neutrophil-DC Hybrids in Immunity to Invasive Fungal Infections. PLoS Pathog. 2018, 14, e1007073.
  30. Yáñez, A.; Coetzee, S.G.; Olsson, A.; Muench, D.E.; Berman, B.P.; Hazelett, D.J.; Salomonis, N.; Grimes, H.L.; Goodridge, H.S. Granulocyte-Monocyte Progenitors and Monocyte-Dendritic Cell Progenitors Independently Produce Functionally Distinct Monocytes. Immunity 2017, 47, 890–902.e4.
  31. Satoh, T.; Nakagawa, K.; Sugihara, F.; Kuwahara, R.; Ashihara, M.; Yamane, F.; Minowa, Y.; Fukushima, K.; Ebina, I.; Yoshioka, Y.; et al. Identification of an Atypical Monocyte and Committed Progenitor Involved in Fibrosis. Nature 2017, 541, 96–101.
  32. Askenase, M.H.; Han, S.-J.; Byrd, A.L.; Morais da Fonseca, D.; Bouladoux, N.; Wilhelm, C.; Konkel, J.E.; Hand, T.W.; Lacerda-Queiroz, N.; Su, X.; et al. Bone-Marrow-Resident NK Cells Prime Monocytes for Regulatory Function during Infection. Immunity 2015, 42, 1130–1142.
  33. Ikeda, N.; Asano, K.; Kikuchi, K.; Uchida, Y.; Ikegami, H.; Takagi, R.; Yotsumoto, S.; Shibuya, T.; Makino-Okamura, C.; Fukuyama, H.; et al. Emergence of Immunoregulatory Ym1 + Ly6C hi Monocytes during Recovery Phase of Tissue Injury. Sci. Immunol. 2018, 3, eaat0207.
  34. Calcagno, D.M.; Ng, R.P.; Toomu, A.; Zhang, C.; Huang, K.; Aguirre, A.D.; Weissleder, R.; Daniels, L.B.; Fu, Z.; King, K.R. The Myeloid Type I Interferon Response to Myocardial Infarction Begins in Bone Marrow and Is Regulated by Nrf2-Activated Macrophages. Sci. Immunol. 2020, 5, eaaz1974.
  35. Fraccarollo, D.; Neuser, J.; Möller, J.; Riehle, C.; Galuppo, P.; Bauersachs, J. Expansion of CD10neg Neutrophils and CD14+HLA-DRneg/Low Monocytes Driving Proinflammatory Responses in Patients with Acute Myocardial Infarction. eLife 2021, 10, e66808.
  36. Swirski, F.K.; Nahrendorf, M.; Etzrodt, M.; Wildgruber, M.; Cortez-Retamozo, V.; Panizzi, P.; Figueiredo, J.-L.; Kohler, R.H.; Chudnovskiy, A.; Waterman, P.; et al. Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites. Science 2009, 325, 612–616.
  37. Leuschner, F.; Panizzi, P.; Chico-Calero, I.; Lee, W.W.; Ueno, T.; Cortez-Retamozo, V.; Waterman, P.; Gorbatov, R.; Marinelli, B.; Iwamoto, Y.; et al. Angiotensin-Converting Enzyme Inhibition Prevents the Release of Monocytes From Their Splenic Reservoir in Mice With Myocardial Infarction. Circ. Res. 2010, 107, 1364–1373.
  38. Senders, M.L.; Meerwaldt, A.E.; van Leent, M.M.T.; Sanchez-Gaytan, B.L.; van de Voort, J.C.; Toner, Y.C.; Maier, A.; Klein, E.D.; Sullivan, N.A.T.; Sofias, A.M.; et al. Probing Myeloid Cell Dynamics in Ischaemic Heart Disease by Nanotracer Hot-Spot Imaging. Nat. Nanotechnol. 2020, 15, 398–405.
  39. Toor, I.S.; Rückerl, D.; Mair, I.; Thomson, A.; Rossi, A.G.; Newby, D.E.; Allen, J.E.; Gray, G.A. Enhanced Monocyte Recruitment and Delayed Alternative Macrophage Polarization Accompanies Impaired Repair Following Myocardial Infarction in C57BL/6 Compared to BALB/c Mice. Clin. Exp. Immunol. 2019, 198, 83–93.
  40. Dutta, P.; Hoyer, F.F.; Grigoryeva, L.S.; Sager, H.B.; Leuschner, F.; Courties, G.; Borodovsky, A.; Novobrantseva, T.; Ruda, V.M.; Fitzgerald, K.; et al. Macrophages Retain Hematopoietic Stem Cells in the Spleen via VCAM-1. J. Exp. Med. 2015, 212, 497–512.
  41. Grisanti, L.A.; Gumpert, A.M.; Traynham, C.J.; Gorsky, J.E.; Repas, A.A.; Gao, E.; Carter, R.L.; Yu, D.; Calvert, J.W.; García, A.P.; et al. Leukocyte-Expressed β2-Adrenergic Receptors Are Essential for Survival After Acute Myocardial Injury. Circulation 2016, 134, 153–167.
  42. Grisanti, L.A.; de Lucia, C.; Thomas, T.P.; Stark, A.; Strony, J.T.; Myers, V.D.; Beretta, R.; Yu, D.; Sardu, C.; Marfella, R.; et al. Prior Beta Blocker Treatment Decreases Leukocyte Responsiveness to Injury. JCI Insight 2019, 4, e99485.
  43. Grisanti, L.A.; Traynham, C.J.; Repas, A.A.; Gao, E.; Koch, W.J.; Tilley, D.G. B2-Adrenergic Receptor-Dependent Chemokine Receptor 2 Expression Regulates Leukocyte Recruitment to the Heart Following Acute Injury. Proc. Natl. Acad. Sci. USA 2016, 113, 15126–15131.
  44. Tanner, M.A.; Maitz, C.A.; Grisanti, L.A. Immune Cell β 2 -Adrenergic Receptors Contribute to the Development of Heart Failure. Am. J. Physiol.-Heart Circ. Physiol. 2021, 321, H633–H649.
  45. Leuschner, F.; Rauch, P.J.; Ueno, T.; Gorbatov, R.; Marinelli, B.; Lee, W.W.; Dutta, P.; Wei, Y.; Robbins, C.; Iwamoto, Y.; et al. Rapid Monocyte Kinetics in Acute Myocardial Infarction Are Sustained by Extramedullary Monocytopoiesis. J. Exp. Med. 2012, 209, 123–137.
  46. Deniset, J.F.; Surewaard, B.G.; Lee, W.; Kubes, P. Splenic Ly6Ghigh Mature and Ly6Gint Immature Neutrophils Contribute to Eradication of S. Pneumoniae. J. Exp. Med. 2017, 214, 1333–1350.
  47. Evrard, M.; Kwok, I.W.H.; Chong, S.Z.; Teng, K.W.W.; Becht, E.; Chen, J.; Sieow, J.L.; Penny, H.L.; Ching, G.C.; Devi, S.; et al. Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. Immunity 2018, 48, 364–379.e8.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback